TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33826449

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation delivered to the common peroneal nerve while walking in addition to standard care
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 64
Study: 35748642

Group type: EXPERIMENTAL
Intervention: Suvorexant 10 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ramelteon 4 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 34335055

Group type: EXPERIMENTAL
Intervention: Active TENS treatment
Number of subjects: 119

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 119
Study: 35264321

Group type: EXPERIMENTAL
Intervention: Mavrilimumab 150 mg subcutaneously every 2 weeks with 26-week prednisone taper
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo with 26-week prednisone taper
Number of subjects: 70
Study: 32407148

Group type: COMPARATOR
Intervention: DIABEO alone (arm 2)
Number of subjects: 665

Group type: COMPARATOR
Intervention: DIABEO+telemonitoring (arm 3)
Number of subjects: 665
Study: 32337932

Group type: EXPERIMENTAL
Intervention: Parental preparation for dental visits (self-preparation)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Parental reliance on dentists for preparation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Dental fear assessment using CFSS-DS
Number of subjects: 67

Group type: COMPARATOR
Intervention: Comparison of dental fear levels by age and gender
Number of subjects: 67

Group type: COMPARATOR
Intervention: Association of parent's dental anxiety and pre-appointment preparation with children's dental fear
Number of subjects: 67
Study: 35949169

Group type: EXPERIMENTAL
Intervention: Consumer-led teaching group (experimental group)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Teaching as usual group (control)
Number of subjects: 217
Study: 36402666

Group type: EXPERIMENTAL
Intervention: Low-level laser acupuncture combined with auricular acupressure (LAA) for 4 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham laser acupuncture treatment (control)
Number of subjects: 76
Study: 33990233

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Suicide Prevention (CTSP) + Treatment as Usual (TAU)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 150
Study: 34724251

Group type: EXPERIMENTAL
Intervention: Roxadustat 2.5 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Roxadustat 1.5 mg/kg and 2.0 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Roxadustat (all doses)
Number of subjects: 24
Study: 33236115

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 316

Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study: 32651711

Group type: EXPERIMENTAL
Intervention: Two-surgeon bilateral TKA
Number of subjects: 246

Group type: COMPARATOR
Intervention: Single-surgeon bilateral TKA
Number of subjects: 246
Study: 34198554

Group type: EXPERIMENTAL
Intervention: HIIT + IF
Number of subjects: 14
Study: 32544082

Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin therapy
Number of subjects: 3044
Study: 34673532

Group type: EXPERIMENTAL
Intervention: Text messaging smoking cessation intervention
Number of subjects: 535

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 535
Study: 35112550

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32780744

Group type: EXPERIMENTAL
Intervention: ADL-IADL-HELP-20
Number of subjects: 1506

Group type: COMPARATOR
Intervention: ADL-IADL-DIFFICULTY-20
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: ADL-IADL-DIFFICULTY-9
Number of subjects: 1506
Study: 34582903

Group type: EXPERIMENTAL
Intervention: Esmolol (1.5 mg/kg bolus followed by 0.1 mg/kg/min infusion)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 69

Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg/kg bolus followed by 1.5 mg/kg/h infusion)
Number of subjects: 69
Study: 37821181

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Non-IRA PCI despite QFR >0.80
Number of subjects: 443

Group type: COMPARATOR
Intervention: Deferred PCI for non-IRA lesions
Number of subjects: 443
Study: 33687025

Group type: EXPERIMENTAL
Intervention: Terbinafine + Itraconazole
Number of subjects: 152

Group type: COMPARATOR
Intervention: Terbinafine
Number of subjects: 152

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 152
Study: 32711541

Group type: EXPERIMENTAL
Intervention: β‐alanine supplementation (4.8 g/day for 6 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: β‐alanine supplementation
Number of subjects: 13
Study: 35675708

Group type: EXPERIMENTAL
Intervention: Pay-it-forward intervention (participants receive free gonorrhea/chlamydia testing as gifts)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Pay-it-forward intervention
Number of subjects: 301

Group type: COMPARATOR
Intervention: Pay-what-you-want
Number of subjects: 301

Group type: COMPARATOR
Intervention: Standard payment
Number of subjects: 301
Study: 33422558

Group type: EXPERIMENTAL
Intervention: 0.05% atropine
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: 0.025% atropine
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo (switched to 0.05% atropine in the second year)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: All concentrations of atropine
Number of subjects: 350
Study: 35257058

Group type: EXPERIMENTAL
Intervention: Low-dose roxadustat (∼1–1.4 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard-dose roxadustat (∼1.5–2 mg/kg)
Number of subjects: 100
Study: 32639099

Group type: EXPERIMENTAL
Intervention: ASC-enriched fat grafts (≥20 × 106 viable ex vivo‐expanded ASCs per milliliter fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional nonenriched fat grafts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASC-enriched fat grafts
Number of subjects: 0
Study: 35553816

Group type: EXPERIMENTAL
Intervention: Dox (5 mg/kg/week)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Es-Exos (50 ug/animal/twice a week)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dox+Es-Exos
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (Con)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MEF-Exos (50 ug/animal/twice a week)
Number of subjects: 10
Study: 32555091

Group type: EXPERIMENTAL
Intervention: Italian version of the Foot‐and‐Ankle‐Disability‐Index (FADI) questionnaire
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FADI questionnaire
Number of subjects: 60
Study: 34789840

Group type: EXPERIMENTAL
Intervention: Blue-green light (478/490/497 nm)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Blue light (459/452/459 nm)
Number of subjects: 3
Study: 34961542

Group type: EXPERIMENTAL
Intervention: New regression formula (SSD, AL, SSW)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Holladay 1
Number of subjects: 121

Group type: COMPARATOR
Intervention: SRK/T
Number of subjects: 121

Group type: COMPARATOR
Intervention: Haigis
Number of subjects: 121
Study: 35064786

Group type: EXPERIMENTAL
Intervention: 2.5D SSD model
Number of subjects: 127

Group type: COMPARATOR
Intervention: 2D model
Number of subjects: 127
Study: 33069281

Group type: EXPERIMENTAL
Intervention: 2 μg vaccine
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: 4 μg vaccine
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: 8 μg vaccine
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: 8 μg vaccine on day 0
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: 4 μg vaccine on days 0 and 14
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: 4 μg vaccine on days 0 and 21
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: 4 μg vaccine on days 0 and 28
Number of subjects: 640

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 640
Study: 35608490

Group type: EXPERIMENTAL
Intervention: Cochlear implantation virtual reality simulation training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Mastoidectomy virtual reality simulation training alone
Number of subjects: 18
Study: 32243316

Group type: EXPERIMENTAL
Intervention: Forced cough during colposcopy-guided cervical biopsy
Number of subjects: 110

Group type: COMPARATOR
Intervention: No cough during colposcopy-guided cervical biopsy
Number of subjects: 110
Study: 35922472

Group type: EXPERIMENTAL
Intervention: Weight reduction intervention
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (no weight reduction intervention)
Number of subjects: 195
Study: 33356421

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (FP) plus oxaliplatin
Number of subjects: 5457
Study: 33252543

Group type: EXPERIMENTAL
Intervention: Photopic luminance
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mesopic luminance
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Peripheral contour interaction (Mesopic)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Peripheral contour interaction (Photopic)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Foveal contour interaction
Number of subjects: 5

Group type: COMPARATOR
Intervention: Peripheral contour interaction
Number of subjects: 5
Study: 34914037

Group type: EXPERIMENTAL
Intervention: Glycerol levels in brain and subcutaneous adipose tissue measured through microdialysis.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Computed tomography Rotterdam score
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Biochemical biomarkers S-100B and neuron-specific enolase (NSE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Injury Severity Score (ISS) and Acute Physiology and Chronic Health Evaluation Score (APACHE II)
Number of subjects: 48
Study: 34607175

Group type: EXPERIMENTAL
Intervention: E2 valerate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 35249510

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (Plac)
Number of subjects: 24
Study: 32919015

Group type: EXPERIMENTAL
Intervention: Resistance training (RET)
Number of subjects: 30
Study: 34719872

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at weeks 0 and 4 and then every 8 weeks
Number of subjects: 739

Group type: COMPARATOR
Intervention: guselkumab (placebo group crossover to guselkumab 100 mg every 4 weeks at week 24)
Number of subjects: 739
Study: 34776002

Group type: EXPERIMENTAL
Intervention: Vitamins A, B, C, D, and E supplementation (25,000 IU daily of A, 600,000 IU once of D, 300 IU twice daily of E, 500 mg four times daily of C, one amp daily of B complex for 7 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no vitamins or placebo)
Number of subjects: 60
Study: 34929196

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention to support caregivers (details not specified)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Resources, strategies, and practices perceived as helpful (details not specified)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Vaccination and testing protocols (details not specified)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Supports for bereaved caregivers (details not specified)
Number of subjects: 125
Study: 34291527

Group type: EXPERIMENTAL
Intervention: Game training (50 min, three times per week for 8 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Regular nursing care
Number of subjects: 72
Study: 32367188

Group type: EXPERIMENTAL
Intervention: cQFR (contrast-flow quantitative flow ratio)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: cQFR
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Diameter stenoses (DS) and area stenoses (AS) in vessels with positive stress MRI
Number of subjects: 87
Study: 34973154

Group type: EXPERIMENTAL
Intervention: L-arginine (6 g/day for 3 months)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 34393125

Group type: EXPERIMENTAL
Intervention: Diode laser disinfection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasonic activated irrigation with 2.5% NaOCl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional irrigation with 2.5% NaOCl
Number of subjects: 60
Study: 35675606

Group type: EXPERIMENTAL
Intervention: Clindamycin 2% gel
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 33216421

Group type: EXPERIMENTAL
Intervention: Quercetin (500 mg/day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 34369402

Group type: EXPERIMENTAL
Intervention: Suction (S+) during EBUS‐TBNA
Number of subjects: 59

Group type: COMPARATOR
Intervention: No suction (S-) during EBUS‐TBNA
Number of subjects: 59
Study: 34551584

Group type: EXPERIMENTAL
Intervention: Lumateperone 42 mg/day
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study: 36154666

Group type: EXPERIMENTAL
Intervention: Throat spray with selected Lactobacilli (verum group, n=41)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (control group, n=37)
Number of subjects: 78
Study: 33631360

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Self-Regulation (SR)
Number of subjects: 288
Study: 34004447

Group type: EXPERIMENTAL
Intervention: Working memory updating training using neutral stimuli
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Working memory updating training using negative stimuli
Number of subjects: 124

Group type: COMPARATOR
Intervention: Non-adaptive working memory updating training
Number of subjects: 124
Study: 32302659

Group type: EXPERIMENTAL
Intervention: Dextran-based prime
Number of subjects: 80

Group type: COMPARATOR
Intervention: Crystalloid prime
Number of subjects: 80
Study: 33819474

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1843
Study: 32014057

Group type: EXPERIMENTAL
Intervention: Aim2Be app with health coaching
Number of subjects: 200

Group type: COMPARATOR
Intervention: Waitlist control group (no access to health coaching)
Number of subjects: 200
Study: 32580841

Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 0.1mg/kg intravenous injection 10 mins before anesthesia induction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline 10 ml intravenous injection
Number of subjects: 60
Study: 33321380

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET) for 8 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 44
Study: 35562327

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg) + Docetaxel (60 mg/m) or Pemetrexed (500 mg/m)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m) or Pemetrexed (500 mg/m) without gefitinib
Number of subjects: 22
Study: 34271122

Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor (CNTF)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Interleukin (IL-17)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Interferon-γ-inducible protein 10 (IP-10)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor (HGF)
Number of subjects: 42
Study: 34387527

Group type: EXPERIMENTAL
Intervention: Er:YAG laser therapy plus 4% hydroquinone (HQ)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intraderal tranexamic acid (TA) plus 4% hydroquinone (HQ)
Number of subjects: 31
Study: 35254433

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) system
Number of subjects: 8937

Group type: COMPARATOR
Intervention: Control group (no CDS system)
Number of subjects: 8937
Study: 32241260

Group type: EXPERIMENTAL
Intervention: Integrated home-environmental intervention package and early child development programme
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Indoor kitchen air quality measurements
Number of subjects: 317
Study: 35944061

Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34444403

Group type: EXPERIMENTAL
Intervention: TRT + Parenting (TRT + P)
Number of subjects: 119

Group type: COMPARATOR
Intervention: TRT
Number of subjects: 119

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 119
Study: 32498620

Group type: EXPERIMENTAL
Intervention: Mavacamten, once-daily oral administration for 30 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, matching placebo for 30 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35790955

Group type: EXPERIMENTAL
Intervention: Resin sealant (etch-and-rinse + Conceal F)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Giomer sealant (self-etch primer + BeautiSealant)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Conventional resin sealants
Number of subjects: 39

Group type: COMPARATOR
Intervention: Giomer sealants
Number of subjects: 39
Study: 33674221

Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 78
Study: 32854972

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1000
Study: 35213351

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided hydrodilatation of glenohumeral joint combined with acupotomy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Ultrasound-guided hydrodilatation of glenohumeral joint
Number of subjects: 63
Study: 34127029

Group type: EXPERIMENTAL
Intervention: Aerobic exercise and health behaviour support
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Aerobic exercise and no health behaviour support
Number of subjects: 264

Group type: COMPARATOR
Intervention: Stretching-toning and health behaviour support
Number of subjects: 264

Group type: COMPARATOR
Intervention: Stretching-toning and no health behaviour support
Number of subjects: 264
Study: 32778531

Group type: EXPERIMENTAL
Intervention: Driver's Risk Field (DRF) assessment using 77 positions of obstacles in a driving simulator
Number of subjects: 8
Study: 35139105

Group type: EXPERIMENTAL
Intervention: Mifepristone 600mg followed by misoprostol
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo followed by misoprostol
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Mifepristone followed by misoprostol
Number of subjects: 351
Study: 34181449

Group type: EXPERIMENTAL
Intervention: Bedside presentation group (n = 476)
Number of subjects: 919

Group type: COMPARATOR
Intervention: Outside the room presentation group (n = 443)
Number of subjects: 919
Study: 36480545

Group type: EXPERIMENTAL
Intervention: Immunisation health education intervention based on Social Cognitive Theory, delivered through five health education sessions.
Number of subjects: 392

Group type: COMPARATOR
Intervention: Usual care (standard care)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Immunisation health education intervention
Number of subjects: 392
Study: 33270229

Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no mirror therapy)
Number of subjects: 26
Study: 35228490

Group type: EXPERIMENTAL
Intervention: Vitamin D 200,000 IU (single dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 34128838

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice a day for 14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 34620035

Group type: EXPERIMENTAL
Intervention: My Guide smartphone application
Number of subjects: 78

Group type: COMPARATOR
Intervention: My Health smartphone application (attention-control condition)
Number of subjects: 78
Study: 32917672

Group type: EXPERIMENTAL
Intervention: Motivationally informed antidoping intervention for coaches (workshops and supplementary information)
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Motivationally informed antidoping intervention for coaches
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Standard antidoping workshop (control group)
Number of subjects: 1049
Study: 35019238

Group type: COMPARATOR
Intervention: Etavopivat (single oral dose)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Etavopivat (14 days of multiple ascending doses)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Etavopivat
Number of subjects: 90
Study: 32888814

Group type: EXPERIMENTAL
Intervention: Video interpretation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone interpretation
Number of subjects: 0
Study: 36204960

Group type: EXPERIMENTAL
Intervention: 3D printing removable dentures
Number of subjects: 80

Group type: COMPARATOR
Intervention: Plaster casting removable dentures
Number of subjects: 80
Study: 33766069

Group type: EXPERIMENTAL
Intervention: Breastfeeding satisfaction measured by the Maternal Breastfeeding Evaluation Scale
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Breastfeeding satisfaction
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Maternal educational level, parity, multiple birth, or maternal birth country other than Sweden
Number of subjects: 493
Study: 32327255

Group type: EXPERIMENTAL
Intervention: Tube shunt surgery (350‐mm2 Baerveldt implant)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (MMC) (0.4 mg/ml for 4 minutes)
Number of subjects: 122
Study: 35020797

Group type: EXPERIMENTAL
Intervention: 2 g cefazolin administered before incision
Number of subjects: 457

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 457
Study: 33714508

Group type: EXPERIMENTAL
Intervention: Deep dry needling technique + routine physical therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hong's dry needling technique + routine physiotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine physical therapy
Number of subjects: 66